Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Camrelizumab in Refractory non MSI-H/dMMR Colorectal Cancer
NCT04866862Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2021
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, camrelizumab in colorectal cancer (CRC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
fruquintinibcamrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04866862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866862.